DNA Repair Drugs Market – Size, Share, Outlook,
and Opportunity Analysis, 2019 – 2026
DNA can be damaged due to endogenous factors (oxidation) or exogenous factors (UV radiations
or viruses), but our cell can identify and repair the damage. However, when the repairing
mechanism of the cell fails, it leads to dysfunctionality or mutations in the DNA of the cell. It
can also lead to abnormal growth of cells, i.e., cancer. Such irreparable damage can be treated
with DNA repair drugs such as poly ADP-ribose polymerase inhibitors (PARP). PARP blocks the
activity of ADP-ribose polymerase proteins, thus preventing the replication of cancer cells.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2617
Global DNA Repair Drugs Market Drivers
Increasing collaboration and acquisition activities are expected to boost the global DNA repair
drugs market growth. For instance, in January 2017, Merck KGaA entered into a licensed
agreement with Vertex Pharmaceuticals Inc., for four research developments on approaches to
cancer. The reason for the partnership was to strengthen Merck’s area of DNA damage response
and immuno-oncology. Furthermore, in February 2016, Onxeo, an orphan oncology therapeutics
company, acquired DNA Therapeutics, a biopharmaceutical company for its DNA repairing
technology for treatment of cancer. This technology consists of a signal interfering DNA
molecule (siDNA), and Onxeo S.A. intends to develop this technology as a potential treatment
option for cancer. Such partnerships are expected to propel the global DNA repair drugs market
growth.
Moreover, frequent research and development activities are expected to propel the global DNA
repair drugs market growth. For instance, in October 2018, Pfizer began conducting a trial of
talazoparib drug for the treatment of triple negative breast cancer. Currently, it’s in second
phase of clinical trial and it is a type of monotherapy. Furthermore, there are many other
products that are in pipeline. For instance, in February 2019, BeiGene began with its clinical
trials of pamiparib for the treatment of metastatic prostate cancer. The trial of pamiparib is
currently in its second phase. Such key researches are expected to boost the global DNA repair
drugs market growth.